Back to News
Market Impact: 0.35
AbbVie's EPKINLY Receives Health Canada Approval For Follicular Lymphoma
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Health Canada issued a Notice of Compliance for AbbVie's EPKINLY (epcoritamab) combined with lenalidomide and rituximab for adults with relapsed or refractory Grade 1, 2, or 3a follicular lymphoma after at least one prior treatment line. The approval expands EPKINLY's addressable use in Canada and is a positive regulatory milestone for AbbVie's oncology portfolio.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
ABBV0.72
More News
- 3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026
- Nvidia's CEO turmoil gives newly empowered Democrats fresh ammunition in pursuit of oversight
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Musk says Tesla will refund some Cybertruck deposits, defends decision to end production
- UniCredit CEO Plots Commerzbank Governance Overhaul